Stocks to buy for 2026: Max Healthcare, Amber Enterprises among 4 stocks that could give 20-40% return in 1 year – Brokerage Recommendations
https://img.etimg.com/thumb/msid-126112778,width-1070,height-580,overlay-etmarkets/slideshow.jpg
Citi on Divis Laboratories Ltd: Buy| Target Rs 9140| LTP Rs 6380| Potential Upside 43%
Citi has reaffirmed its Buy rating on Divi’s Laboratories, assigning a target price of Rs 9,140, which translates into a potential upside of 43% from the current market price of Rs 6,380.
(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
Post Comment